Development of Models, New Approach Methodologies, and Biological Materials for Studying Human Health and Diseases (R21 Clinical Trial Not Allowed)
Funding Amount
$190K – $500K
Deadline
Forecast — expected February 16, 2028
Forecast by the agency; not yet open
Number of Awards
15
Grant Type
Federal
Deadline history & next window
- Cycle
- Not stated
- Next expected
- February 16, 2028
- Tracked since
- September 2026
Forecast: expected to post December 16, 2027; applications expected due February 16, 2028.
Source: Grants.gov forecast for this opportunity.
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Special district governments
- Tribal organizations
- Tribal governments
- State governments
- Small businesses
- County governments
- Private colleges & universities
- School districts
Geography
- Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Overview
This notice of funding opportunity (NOFO) encourages innovative research to develop, characterize, improve or preserve research models and model related biological materials, and to develop or improve technologies, including new approach methodologies (NAMs), for studies relevant to human health and diseases. This NOFO also seeks projects aimed at improving the identification and control of factors that could confound or interfere with the use of research models in biomedical research. The proposed studies must include research model(s) or NAM(s) and must explore multiple body systems or multiple categories of diseases affecting multiple body systems. Applications that develop models focused on a specific disease, a narrow area of research, or a single body system, or propose studies primarily relevant to a single NIH IC will be considered not acceptable to this NOFO.
Full eligibility text
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Focus Areas & Funding Uses
Fields of Work
- Health
Related Grants
Open grants from this funder and similar programs
Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required)
National Institutes of Health
Amount
Varies
Deadline
October 6, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
National Institutes of Health
Amount
Up to $1M
Deadline
October 9, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 9, 2026
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$650,000 total
Deadline
October 9, 2026
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
National Institutes of Health
Amount
$5,000,000 total
Deadline
October 11, 2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Ready to apply for Development of Models, New Approach Methodologies, and Biological Materials for Studying Human Health and Diseases (R21 Clinical Trial Not Allowed)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Development of Models, New Approach Methodologies, and Biological Materials for Studying Human Health and Diseases (R21 Clinical Trial Not Allowed). Now let's win it.